Browse News
Filter News
Found 26 articles
-
Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held January 9-12, 2023 in San Francisco, CA.
-
While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.
-
Korro Bio Expands Leadership Team with Key Appointments
11/8/2022
Korro Bio, Inc today announced the appointment of Venkat Krishnamurthy, Ph.D., as Senior Vice President, Head of Platform and Stephanie Engels as Senior Vice President, Head of People and Culture.
-
Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up
9/13/2022
Delix Therapeutics (the "Company"), a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, has been named to Nature Biotechnology's list of leading spinouts of 2021.
-
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
-
Korro Bio to Participate in 2022 Jefferies Healthcare Conference
6/6/2022
Korro Bio, Inc. announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New York, NY, on Thursday, June 9, 2022, at 10:30 a.m. EDT.
-
Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
1/26/2022
Senda Biosciences, Inc., a company that is harnessing nature to program targeted, potent and tunable medicines, has appointed Stuart Milstein, Ph.D., to the newly created position of Senior Vice President and Head of Platform Biology.
-
With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.
-
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
1/5/2022
Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors.
-
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/22/2021
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Participate in September Investor Conferences
8/31/2021
Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Wells Fargo Healthcare Conference and participate in a fireside chat at the 2021 Morgan Stanley Global Healthcare Conference.
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at 2021 Jefferies Virtual Healthcare Conference
5/25/2021
Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. EDT.
-
BioSpace Movers & Shakers, May 14
5/14/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers. -
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
5/11/2021
Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer.
-
Korro Bio Strengthens Leadership Team With Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
4/1/2021
Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Howard Stern, M.D., Ph.D. as Chief Scientific Officer. Dr. Stern is a seasoned biotechnology executive with extensive experience in drug discovery and development,
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
3/5/2021
Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the Barclays Global Healthcare Conference and the WuXi Healthcare Forum this month.
-
Korro Bio to Present at J.P. Morgan Healthcare Conference
1/7/2021
Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present an update on Korro’s progress at the 39 th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 14, 2021 at 8:05 a.m. E.T. using a virtual platform. About Korro Bio, Inc. Korro is leading the
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
BioSpace Announces Top New Life Sciences Companies to Watch in 2021
1/6/2021
BioSpace, Inc., the leading life sciences news and careers site, has announced their 25 selections for biopharma's most promising up-and-coming companies in 2021.